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Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus
establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease.
Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα for tumor-directed
delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule
dynamics. Here, combinations of IMGN853 with approved therapeutics were evaluated in preclinical models of
EOC. Combinations of IMGN853 with carboplatin or doxorubicin resulted in synergistic antiproliferative effects in
the IGROV-1 ovarian cancer cell line in vitro. IMGN853 potentiated the cytotoxic activity of carboplatin via growth
arrest and augmented DNA damage; cell cycle perturbations were also observed in cells treated with the
IMGN853/doxorubicin combination. These benefits translated into improved antitumor activity in patient-derived
xenograft models in vivo in both the platinum-sensitive (IMGN853/carboplatin) and platinum-resistant (IMGN853/
pegylated liposomal doxorubicin) settings. IMGN853 co-treatment also improved the in vivo efficacy of
bevacizumab in platinum-resistant EOC models, with combination regimens causing significant regressions and
complete responses in the majority of tumor-bearing mice. Histological analysis of OV-90 ovarian xenograft tumors
revealed that concurrent administration of IMGN853 and bevacizumab caused rapid disruption of tumor
microvasculature and extensive necrosis, underscoring the superior bioactivity profile of the combination regimen.
Overall, these demonstrations of combinatorial benefit conferred by the addition of the first FRα-targeting ADC to
established therapies provide a compelling framework for the potential application of IMGN853 in the treatment of
patients with advanced ovarian cancer.
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Ovarian cancer remains the leading cause of gynecologic cancer
mortality, responsible for more than 140,000 deaths worldwide each
year [1]. In the United States alone, an estimated 22,280 new cases
will be seen and 14,240 women will die due to this disease in 2016
[2]. Epithelial ovarian cancer (EOC), which is typically diagnosed at
an advanced stage, accounts for over 95% of ovarian malignancies
[3,4]. Debulking surgery followed by combination chemotherapy
with a platinum-based regimen is the foundation of current standard
of care treatment; unfortunately, this approach has largely reached a
plateau of effectiveness in improving overall patient survival [5,6].
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patients achieve remission with front-line therapy, up to 80% of
women ultimately relapse with drug-resistant disease [7]. The
prognosis for individuals with recurrent and/or platinum-resistant
EOC continues to be poor with no curative therapeutic options —
thus, there exists a substantial unmet medical need for novel
approaches to improve clinical outcomes in this malignancy.
An increased understanding of the biological and genomic
complexity of EOC has led to the exploration of molecularly targeted
strategies designed to shift treatment away from broad-based cytotoxic
use toward more tailored interventions [4,6]. However, only two new
drugs have been approved for EOC therapy in the last 5 years — the
angiogenesis inhibitor bevacizumab and the PARP inhibitor olaparib
[8] — both of which target oncogenic pathways linked to ovarian
tumorigenesis. Another molecular target of considerable interest is the
cell surface glycoprotein folate receptor alpha (FRα) [9]. In contrast to
its restricted expression pattern in normal tissues [10], high FRα
expression is characteristic of a variety of epithelial tumors, including
EOC [11,12]. Elevated FRα expression has been observed in more
than 70% of primary and 80% of recurrent ovarian cancers [13], and
evidence suggests that increased receptor levels may be associated with
more poorly differentiated, aggressive tumors as well as resistance to
conventional chemotherapy [14–16].
The differential distribution of FRα has been investigated as a
means to selectively target tumors in order to maximize antitumor
efficacy and treatment tolerability [17]. The humanized anti-FRα
monoclonal antibody farletuzumab was investigated to determine
whether it could exert clinically relevant antitumor activity through
antibody-dependent cell-mediated cytotoxicity and complement-
dependent cytotoxicity [18]. Two short–half-life folate-payload
conjugates, BMS-753493 with a semisynthetic analog of epothilone
A [19] and vintafolide (EC145) with a vinca alkaloid [20,21], have
each been examined as a means of selectively delivering a cytotoxic
agent directly to cancer cells with high folate receptor expression.
Unfortunately, none of these approaches have yet shown meaningful
efficacy in ovarian cancer trials [22,23].
Antibody-drug conjugates (ADCs), which comprise a cytotoxic
payload conjugated to an antibody directed against a tumor-
associated antigen [24,25], are a validated therapeutic approach for
the treatment of solid tumors [26,27]. Mirvetuximab soravtansine
(IMGN853) is an ADC that consists of a cytotoxic effector
compound, the maytansinoid DM4, coupled to a humanized
anti-FRα monoclonal antibody via a linker that is stable in the
circulation but readily cleaved within cells to release the payload
[25,28]. Use of an antibody as the targeting vehicle provides antigen
specificity (i.e., selective targeting of FRα instead of general folate
receptors) as well as an extended half-life to ensure adequate delivery
of the agent to the site of tumors. High-affinity binding of IMGN853
to FRα followed by its internalization results in accumulation of a
high cytotoxic intracellular concentration of DM4 [29], which
subsequently acts as a potent antimitotic agent through its ability to
suppress microtubule dynamics [30,31]. Confirming design expec-
tations, IMGN853 exhibited robust single-agent antitumor activity
against FRα-expressing tumors, including preclinical models of
ovarian cancer [32].
The clinical experience in EOC has shown that addition of a third
cytotoxic agent to existing standard-of-care chemotherapeutic
regimens results in increased toxicity without improving disease
control [33,34]. Another strategy for improving patient outcomesinvolves combining targeted agents, possessing distinct mechanisms
of action and favorable tolerability, with established chemotherapeu-
tics [35]. Validation of this approach is exemplified by the recent
approval of bevacizumab for use alongside paclitaxel, pegylated
liposomal doxorubicin (PLD), or topotecan in platinum-resistant,
recurrent disease [36,37]. Importantly, the maturing clinical profile of
IMGN853 has revealed manageable safety and encouraging evidence
of single-agent therapeutic efficacy, particularly in patients with EOC
[38]. These considerations thus prompted an evaluation of the
combinatorial activity of IMGN853 with a variety of clinically
relevant agents in preclinical ovarian cancer models. The findings
presented here support the use of IMGN853 in combination with
conventional therapies in both the front-line and recurrent settings
and further underscore the therapeutic potential of this FRα-targeting
ADC for the management of ovarian cancer.
Materials and Methods
Cell Lines, Antibodies, and Reagents
The OV-90 and IGROV-1 human ovarian adenocarcinoma cell
lines were purchased from the ATCC (Rockville, MD) and Division
of Cancer Treatment and Diagnostics, National Cancer Institute
(Frederick, MD), respectively, and maintained according to manu-
facturers' instructions. The γH2AX, β-actin, and CD31 antibodies
were purchased from Cell Signaling Technology (Danvers, MA); the
anti-maytansinoid mouse monoclonal antibody was generated at
ImmunoGen Inc. (Clone CAA-162). IMGN853, consisting of the
maytansinoid DM4 [N2′-deacetyl-N2′-(4-mercapto-4-methyl-1-
oxopentyl)-maytansine] coupled to the anti-FRα antibody M9436A
via an N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate linker,
was prepared at ImmunoGen as described previously [32].
Carboplatin and doxorubicin used for the in vitro assays were
purchased from Sigma-Aldrich (St. Louis, MO). The carboplatin
and bevacizumab formulations used for the in vivo experiments
performed in-house were purchased from RxUSA Pharmacy (Port
Washington, NY).
In Vitro Drug Interaction Analysis
IGROV-1 cells were seeded at a density of 1 × 103 cells/well in
100 μl of growth medium (Eagle's minimum essential medium,
ATCC), supplemented with 10% fetal bovine serum, in 96-well
plates. Drugs were diluted in growth medium, and 100 μl volumes
were added to the cells before incubation at 37°C, 6% CO2 for
5 days. Cell viability was determined using the WST8 assay
(Donjindo Molecular Technologies, Inc., Rockville, MD) according
to the manufacturers' protocol. The nature of the IMGN853-
chemotherapeutic combination interactions was evaluated using the
Combination Index (CI) method of Chou and Talalay [39] and
values generated using Median Effect analysis. IMGN853 was mixed
with carboplatin or doxorubicin at an equipotent fixed molar ratio
(IC50 values) and cells exposed to a range of drug concentrations that
resulted in cell killing between 0% and 100% of cells. As controls,
single agents and untreated cells (exposed to medium only) were
included in each experiment. CI values were generated by CalcuSyn
Software (Biosoft, Cambridge, UK). CI values were plotted versus
fraction affected (i.e., fraction of killed cells) for each independent
experiment. Objective criteria were applied to drug interaction
analysis: the effect was considered synergistic at CI b0.75, additive at
CI 0.75 to 1.25, and antagonistic at CI N1.25.
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IGROV-1 cells were exposed to 8 nM IMGN853, 20 μM
carboplatin, and 200 nM doxorubicin, alone and in combination, for
6 hours at 37°C. After washout, cells were cultured in drug-free
growth medium for an additional 18 hours. At this time point, cells
were harvested, permeabilized with 70% ethanol, and stained with
propidium iodide (Roche Diagnostics Corporation, Indianapolis,
IN). Cells were analyzed for DNA content using a FACSCalibur flow
cytometer (BD Biosciences, San Diego, CA). Each sample was
analyzed in duplicate, and two independent experiments were
performed; representative results are shown as percentage of the
cells in the G0/G1, S, and G2/M phase of the cell cycle.
Western Blotting
IGROV-1 cells were cultured with IMGN853 and carboplatin,
alone and in combination, for 6 hours at 37°C followed by additional
18-hour incubation in drug-free growth medium. Following
treatment, the tumor cells were disrupted in a RIPA lysis buffer
containing protease and phosphatase inhibitors (Thermo Fisher
Scientific, Waltham, MA). Lysates were clarified by centrifugation,
and equal amounts of protein (15 μg) were resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis under reducing
conditions before transfer to nitrocellulose membranes. Membranes
were blocked with SuperBlock T20 (Thermo Fisher Scientific).
Primary anti-γH2AX and β-actin antibodies were diluted in the same
buffer and incubated with the membrane overnight; bound antibody
was detected using horseradish peroxidase–conjugated anti-rabbit or
anti-murine secondary antibody, respectively (Jackson ImmunoR-
esearch Laboratories, West Grove, PA), and ECL detection
(Amersham; GE Healthcare Life Sciences, Pittsburgh, PA). For the
pharmacodynamic analysis, xenograft tumor samples from vehicle-,
IMGN853-, bevacizumab-, or combination-treated mice were lysed
using a Percellys 24 homogenizer (Bertin Corp., Rockville, MD), and
lysates were processed and analyzed as above.
In Vivo Xenograft Studies
Female severe combined immunodeficient (SCID) mice were
obtained from Charles River Laboratories (Wilmington, MA) and
quarantined for 7 days prior to study initiation. All procedures were
performed in strict accordance with the NIH Guide for the Care and
Use of Laboratory Animals. Mice were housed in self-contained
microisolator cages in climate-controlled suites for all studies. Food
and water were available ad libitum. Xenografts were established by
subcutaneous inoculation of cells; when tumors reached an average
size of approximately 100 mm3, mice were randomized by tumor
volume into treatment groups (six to eight animals/group) and given
an intravenous (IV) bolus dose of test article via the tail vein.
Carboplatin was additionally administered via intraperitoneal (IP)
dosing in one experiment. Patient-derived xenograft (PDX) studies
were performed at South Texas Accelerated Research Therapeutics
(START) (San Antonio, TX) under an institutional review board–
approved protocol. The doses and treatment regimens for each group
are described in detail in the respective figures.
Tumor volumes were quantitated over time, and as a measure of in
vivo efficacy, treatment over control (T/C) values were determined
from the change in average tumor volumes in each treated group
relative to either the vehicle-treated or itself in the case of tumor
regression. T/C values were calculated as T/C (%) = (ΔT/ΔC) × 100,
for ΔT N 0, or T/T0 (%) = (ΔT/T0) × 100, for ΔT b 0, where ΔT isthe change in mean tumor volume of treatment cohort from day 1 to
end point, ΔC is the change of mean tumor volume of vehicle cohort
from day 1 to end point, and T0 is the mean tumor volume of
treatment cohort on day 1. A complete tumor regression (CR) was
scored when no palpable tumor could be detected.
Immunohistochemistry
OV-90 xenograft-bearing mice were treated with a single dose of
vehicle, IMGN853 (2.5 mg/kg), bevacizumab (5 mg/kg), or
IMGN853 plus bevacizumab. Tumors were excised 4 days later
and fixed in 10% neutral buffered formalin overnight at ambient
temperature. Paraffin-embedded sections were subject to immuno-
histochemical staining for CD31 and anti-maytansine using a
Ventana Discovery Ultra autostainer (Roche Diagnostics). To
determine histopathology changes, tumor sections were stained
with hematoxylin and eosin (H&E) using standard protocols.
Results
The Combination of IMGN853 with Carboplatin Promotes
Synergistic Growth Inhibitory Effects and Cell Cycle Perturbations
In Vitro
For over a decade, carboplatin in combination with paclitaxel has
represented the chemotherapeutic standard of care for EOC patients
in the first-line adjuvant setting [6]. To test whether IMGN853
co-treatment could improve the activity of carboplatin in EOC, we
initially evaluated the combinatorial effects of IMGN853 (Figure 1A)
and carboplatin exposure in inhibiting growth of the platinum-
sensitive ovarian carcinoma cell line IGROV-1. IGROV-1 cells were
treated in vitro with increasing concentrations of IMGN853,
carboplatin, or both, and combinatorial activity was assessed using
median effect analysis (Figure 1B). The combination was synergistic,
indicating that IMGN853 augmented the effects of the platinum
compound in these ovarian tumor cells.
Cell cycle analysis revealed that carboplatin exposure resulted in an
accumulation of IGROV-1 cells in both the S and G2/M phases
(Figure 1C), effects previously reported to precede cell death induced
by this agent in ovarian lines [40,41]. Treatment with IMGN853
alone resulted in an enrichment of cells in G2/M in accordance with
the well-established antimitotic activity of maytansinoids [30,31].
Consistent with these results, co-treatment with both agents resulted
in almost half of all viable cells accumulating in G2/M. We also
examined expression changes in the phosphorylated form of histone
H2AX (γH2AX), a sensitive indicator of DNA damage that occurs in
response to alkylating agents or as a result of mitotic catastrophe
[42,43]. Single-agent IMGN853 treatment induced γH2AX expres-
sion in IGROV-1 cells and to levels higher than those seen following
carboplatin exposure alone. Combination treatment augmented the
degree of γH2AX upregulation, indicative of enhanced DNA damage
and consistent with a catastrophic phenotype (Figure 1D).
IMGN853 Potentiates the Antitumor Activity of Carboplatin
In Vivo
To examine whether these in vitro cellular effects translated to
improved efficacy in vivo, mice bearing PDXs obtained from an
individual with EOC were treated with IMGN853 and carboplatin,
both as single agents and in combination (Figure 1E). We had
previously determined that IMGN853 exhibited robust single-agent
activity in this platinum-sensitive PDX model (data not shown);
therefore, a suboptimal dose of IMGN853 was selected to permit
Figure 1. IMGN853 potentiates the therapeutic activity of carboplatin in platinum-sensitive and platinum-resistant EOC models. (A)
Structural representation of IMGN853. (B) IGROV-1 cells were treated with graded concentrations of IMGN853, carboplatin, or both,
and the effects on proliferation were determined. The CI was calculated using median effect analysis. Data from two independent
experiments are shown, determined for a range of drug concentrations and a fractional effect (Fa) of 0.4 to 0.7. Data points below the
green line represent synergy between the drug pairs. (C) IGROV-1 cells were treated with carboplatin (20 μM) or IMGN853 (8 nM), both
alone and in combination, for 6 hours. Cells were washed, and cell cycle distribution was determined following 24-hour culture in
drug-free medium. (D) IGROV-1 cells were exposed to carboplatin (40 μM) or IMGN853 (16 nM), alone or in combination, for 6 hours
followed by incubation in drug-free medium for an additional 18 hours. Cellular extracts were immunoblotted for γH2AX or actin
(loading control) as indicated. (E) Platinum-sensitive ovarian cancer PDXs were established in SCID mice. Animals were dosed with a
single administration of IMGN853 (2.5 mg/kg) or carboplatin (80 mg/kg), alone and in combination (n = 7 mice/group). Data are
expressed as mean and SEM for each time point. (F) Mice bearing platinum-sensitive PDX tumors (n = 7 mice/group) received two
consecutive weekly doses of vehicle, carboplatin (80 mg/kg, IP) plus paclitaxel (10 mg/kg), carboplatin plus PLD (4 mg/kg), or
carboplatin plus IMGN853 (5 mg/kg), as indicated.
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Animals received a single administration of IMGN853 (2.5 mg/kg) or
carboplatin (80 mg/kg), and each regimen inhibited tumor growth as
monotherapy (T/C values of 43% and 20% on day 39, respectively).
Consistent with the in vitro findings above, concurrent treatment
with both agents resulted in a substantial enhancement of antitumor
activity, inhibiting tumor growth by 97% (i.e., T/C value, 3%) at thesame time point. Importantly, the combination of IMGN853
with platinum-based therapy was well tolerated, with no toxicity or
loss of body weights seen over the course of the study (Supplementary
Figure S1A).
The combinatorial benefit conferred by IMGN853/carboplatin
treatment thus prompted a comparison of this modality with
clinically relevant chemotherapeutic combinations in the same PDX
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(QW × 2) of carboplatin (80 mg/kg, IP) in combination with IV
paclitaxel (10 mg/kg), PLD (4 mg/kg), or IMGN853 (5 mg/kg). As
expected, treatment with the carboplatin-paclitaxel doublet was
efficacious in this model of platinum sensitivity (Figure 1F).
Combination carboplatin and PLD treatment, commonly indicated in
the platinum-sensitive recurrence setting, was also active in suppressing
tumor growth. Notably, IMGN853 plus carboplatin combination
therapy induced the greatest degree of tumor growth inhibition,
including CRs in six of seven tumor-bearing mice. In contrast, only two
CRs were seen with the carboplatin/PLD combination, and none were
observed in the carboplatin/paclitaxel-treated group. The
carboplatin-paclitaxel doublet was well tolerated in this model, although
some delayed toxicity was observed in animals from the PLD/carboplatin
and IMGN853/carboplatin treated groups (data not shown).
Combined IMGN853 and PLD Treatment Results in Superior
Therapeutic Activity in Platinum-Resistant PDX Tumors
In clinical practice, PLD is a widely used second-line treatment for
recurrent and/or platinum-resistant EOC, with this formulation
showing superior tolerability over doxorubicin [44]. Similar to what
was observed with carboplatin, the combination of IMGN853 and
doxorubicin was synergistic with respect to in vitro antiproliferative
activity in the IGROV-1 cell line (Figure 2A) and resulted in a more
pronounced S plus G2/M cell cycle delay (Figure 2B).Figure 2. The anticancer activity of doxorubicin (in vitro) and PDL (in v
increasing concentrations of IMGN853, doxorubicin, or both, and th
usingmedian effect analysis. Data from three independent experimen
between the drug pair. (B) IGROV-1 cells were treated with doxorubic
6 hours. Cells were washed, and cell cycle distribution was determined
ovarian cancer PDXswere established in SCIDmice. Animals received tw
alone or in combination (n = 8mice/group). Data are expressed asmean
weekly. Mean values are plotted against vehicle controls.To extend the in vitro observations, the combination of IMGN853
and PLD was examined in a platinum-resistant EOC PDX model
(Figure 2C). Vehicle-treated animals progressed quickly and were
removed from study when tumors reached volumes between 1500
and 2000 mm3. QW × 2 dosing of IMGN853 (5 mg/kg) inhibited
tumor growth by 81% on day 49, and a similar degree of inhibition
(83%) was seen when PLD (4 mg/kg) was administered on the same
schedule. Even at these efficacious dose levels, combination treatment
resulted in an improved and sustained antitumor response,
completely abrogating tumor growth in this aggressive model of
EOC. Importantly, all regimens were well tolerated, and the addition
of IMGN853 to PLD conferred no additional toxicity or changes in
body weight compared with PLD treatment alone (Figure 2D). Thus,
within the context of platinum-resistant disease, the combination of
IMGN853 with PLD resulted in superior, durable efficacy compared
with the single-agent activity of either compound alone.
Combinations of IMGN853 with Bevacizumab Are Highly
Efficacious in Platinum-Resistant EOC Xenografts
We also examined the efficacy of in vivo combinations of
IMGN853 and bevacizumab, the only biologic therapy approved for
use in ovarian cancer. OV-90 tumor-bearing mice were administered a
single dose of vehicle, IMGN853 (2.5 mg/kg), bevacizumab (5 mg/kg),
or the combination, and growth was monitored op to 80 days
(Figure 3A). As monotherapy at these dose levels, bevacizumabivo) is enhanced by IMGN853. (A) IGROV-1 cells were treated with
e effects on proliferation were determined. The CI was calculated
ts are shown, with points below the green line representing synergy
in (200 nM) or IMGN853 (8 nM), both alone and in combination, for
following 24-hour culture in drug-free medium. (C) Platinum-resistant
o consecutiveweekly doses of IMGN853 (5mg/kg) and PLD (4mg/kg)
andSEM for each time point. (D) Bodyweightsweremeasured twice
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however, neither agent induced sustained tumor growth inhibition or
tumor regression. In stark contrast, the combination of IMGN853 plus
bevacizumab resulted in robust tumor regressions in all animals (Figure
3A), with CRs observed in six of six mice (Table 1). Notably, similar
combinatorial benefit was achieved when the dose of IMGN853 was
further reduced to 1.25 mg/kg (data not shown). All treatmentsincluding the combination were well tolerated with no toxicity or
effects on body weights seen (Supplementary Figure S1B).
Next, the effects of fractionated bevacizumab dosing were
examined whereby animals were administered bevacizumab as either
a single 5-mg/kg dose or two 2.5-mg/kg doses (QW × 2), both as
monotherapy and in combination with 3 mg/kg IMGN853
(Figure 3B). Split dosing had no effect on bevacizumab efficacy,
and similar (moderate) growth-suppressive effects were seen following
treatment with single-agent IMGN853. Exposure to both combina-
tion regimens resulted in rapid tumor stabilization and dramatic
regressions (up to 38% within 10 days of treatment), particularly in
the IMGN853 plus 5-mg/kg bevacizumab cohort where doublet
therapy was curative for all seven animals (Figure 3B, Table 1). Once
again, combination IMGN853 and bevacizumab treatments were
well tolerated (Supplementary Figure S1C).
Finally, we evaluated IMGN853 efficacy in combination with
bevacizumab in the same platinum-resistant PDX model shown in
Figure 2C. Unlike the moderate activity seen with IMGN853
monotherapy, single-agent bevacizumab exposure (5 mg/kg, dosed
QW × 2) resulted in prolonged growth control of these aggressive
tumors (data not shown), although no CRs were observed over the
course of a 102-day study (Table 1). In agreement with the OV-90
results, the combination of IMGN853 and bevacizumab (both 5mg/kg,
QW × 2) outperformed either single-agent modality and induced
tumor regressions in all mice, as CRs were seen in seven of eight
animals (Table 1). Indeed, analysis of end-of-study tumor volumes
revealed a significant reduction in tumor burden in the combination-
treated group compared with bevacizumab-treated animals alone
(Figure 3C). Moreover, this effect was not recapitulated in animals
that were treated with a combination of bevacizumab and paclitaxel
(10 mg/kg), suggesting that the therapeutic benefit conferred by the
addition of IMGN853 to the antiangiogenic agent is functionally
selective for the ADC molecule.
The IMGN853-Bevacizumab Combination Induces Rapid
Tumor Microvascular Disruption and Extensive Necrotic
Damage in OV-90 Xenografts
Toward a mechanistic understanding of the superior efficacy seen
with the IMGN853 in the presence of bevacizumab in vivo, OV-90
tumors from animals treated with IMGN853 (2.5 mg/kg),Figure 3. In vivo antitumor activity of IMGN853 in combination with
bevacizumab. (A) Mice bearing established OV-90 xenografts (n =
6 mice/group) were IV dosed with a single administration of
IMGN853 (2.5 mg/kg) or bevacizumab (5 mg/kg), alone and in
combination, as indicated. Data are expressed as mean and SEM
for each time point. The combination of IMGN853 and bevacizu-
mab led to prolonged tumor regressions. (B) Mice bearing
established OV-90 xenografts (n = 7 mice/group) received a single
IV injection of IMGN853 (3 mg/kg) alone or in combination with
bevacizumab, administered either as a single 5-mg/kg dose or two
consecutive weekly doses of 2.5 mg/kg (QW × 2). Combination
treatments of IMGN853 with either bevacizumab dosing regimen
were more efficacious than the corresponding single agents.
(C) Mice bearing platinum-resistant ovarian cancer PDXs received
two consecutive weekly doses of bevacizumab (5 mg/kg), alone or
in combinationwith either paclitaxel (10mg/kg) or IMGN853 (5mg/kg),
and tumor growth was monitored out to 102 days. Tumor volumes
were measured at the end of study, and individual tumor sizes were
plotted according to treatment group. *P = .011; **P = .018; ns, not
significant (Wilcoxon test, nonadjusted).
Table 1. Combination IMGN853 and Bevacizumab Treatment Produces a Large Number of CRs
in Platinum-Resistant EOC Xenograft Models
Treatment Group No. of CRs
OV-90 xenografts
Vehicle 0/13
IMGN853 (2.5 mg/kg) 0/6
Bevacizumab (5 mg/kg) 0/6
IMGN853 (2.5 mg/kg) + bevacizumab (5 mg/kg) 6/6
IMGN853 (3 mg/kg) 0/7
Bevacizumab (5 mg/kg) 0/7
Bevacizumab (2.5 mg/kg; QW × 2) 0/7
IMGN853 (3 mg/kg) + bevacizumab (5 mg/kg) 7/7
IMGN853 (3 mg/kg) + bevacizumab (2.5 mg/kg; QW × 2) 6/7
Platinum-resistant PDX
Vehicle 0/8
IMGN853 (5 mg/kg; QW × 2) 0/8
Bevacizumab (5 mg/kg; QW × 2) 0/8
Paclitaxel (10 mg/kg, QW × 2) + bevacizumab (5 mg/kg, QW × 2) 0/7
IMGN853 (5 mg/kg, QW × 2) + bevacizumab (5 mg/kg, QW × 2) 7/8
The numbers of CRs from all experimental groups reported in Figure 3 are tabulated.
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postdosing and examined (Figure 4). It is noteworthy that
combination therapy completely arrested tumor growth at this early
time point, as measured by changes in tumor volumes, in contrast to
only delays seen with corresponding single-agent dosing (e.g., see
Figure 3A). Histological (H&E) staining revealed that tumors from
combination-treated mice were structurally comprised of large
necrotic cores surrounded by a smaller rim of viable cells at the
periphery (Figure 4A). This extent of cellular destruction was not
observed in any of the other treatment groups and is consistent with
the rapid tumor stabilization conferred by the dosing regimen. Next,
as a pharmacodynamic readout, tumor γH2AX levels were measured
by immunoblotting (Figure 4B). As expected, γH2AX expression was
negligible in tumors from vehicle-treated mice but was robustly
induced following single-agent IMGN853 treatment. Consistent
with the observed improvements in antitumor activity, the addition
of bevacizumab to IMGN853 resulted in further elevations in
γH2AX levels relative to those seen with IMGN853 monotherapy.
Interestingly, γH2AX upregulation was also observed in tumors
following bevacizumab exposure alone, albeit to a lesser degree than
IMGN853 (Figure 4B). Although genotoxic insults are the primary
inducers of γH2AX, accumulation of this protein can also occur in
response to hypoxia [45,46]. This result, therefore, suggested that
increased hypoxic conditions arising from bevacizumab-induced
vascular disruption were contributing to the amplified DNA damage
profile. In order to examine treatment-related effects on microvessels,
immunohistochemical staining with the endothelial cell marker
CD31 was performed (Figure 4C, upper panel). Tumors from control
and IMGN853-treated mice had numerous large vessels, which were
decreased in size and showed loss of luminal integrity following
bevacizumab treatment. Notably, dual IMGN853 and bevacizumab
administration led to marked changes in the tumor microvasculature.
These included a clear reduction in the number of large branched
vascular structures, with the smaller CD31-stained areas lacking clear
lumens and predominantly localized to the peripheral rim regions.
Additional staining of corresponding tissue samples with an
anti-maytansinoid antibody confirmed tumor-directed delivery of
IMGN853 in mice treated with the ADC-containing regimens
(Figure 4C, lower panel).Discussion
The characteristic high expression of FRα seen in EOC has made this
cell surface molecule an attractive candidate for therapeutic
intervention in this disease [28,47]. Early clinical evaluations of
antineoplastic agents targeting FRα, including the nonconjugated
antibody (farletuzumab) and folate-cytotoxic agent small molecule
conjugates (BMS-753493 and vintafolide), provided critical
proof-of-concept evidence and validated FRα as a druggable target
for cancer treatment [11,48]. Although found to be well tolerated in
human trials, the application of these agents has been hampered in
large part by a lack of efficacy in pivotal studies either as single agents
or as part of combination approaches [22,23]. Thus, the full potential
of this strategy for improving patient outcomes in ovarian and other
high FRα–expressing cancers remains to be realized. The integration
of molecularly targeted agents that possess alternate mechanisms of
action and nonoverlapping toxicities to established chemotherapeutic
regimens has proven important in the management of a number of
human malignancies [49], a relevant example being the recent
approval of bevacizumab for use alongside conventional cytotoxics in
recurrent, platinum-resistant EOC [36,37]. In this study, we show
that targeted therapy combinations of IMGN853 with clinically
approved agents confer superior therapeutic activity over correspond-
ing single-agent treatments in preclinical models of EOC (including
patient-derived xenografts) in both the platinum-sensitive and
platinum-resistant disease settings.
Ovarian cancer is typically chemosensitive to first-line chemother-
apy, with initial response rates as high as 70% to 80% seen for
patients who receive standard platinum plus paclitaxel–based
treatment. A majority of these women, however, will ultimately
relapse with drug-resistant disease. Recurrent EOC is classified based
on the time to relapse following first-line treatment with a platinum
agent. Relapse within 6 months of completing initial platinum
therapy is classified as primary platinum resistant. Relapse beyond 6
months is classified as platinum-sensitive disease, and these patients
have a high likelihood of responding to additional platinum-based
therapy [50]. Thus, we first examined the potential for IMGN853 to
substitute for paclitaxel, based on their similar modes of action as
microtubule inhibitors, as part of a combinatorial strategy alongside
carboplatin within the context of platinum sensitivity. The
combination of IMGN853 and carboplatin was synergistic in
reducing growth and viability of the IGROV-1 cell line. The
mechanism by which IMGN853 augmented the activity of
carboplatin was likely multifactorial, including complementary effects
on the cell cycle and enhanced DNA damage — a phenotype
consistent with mitotic catastrophe. Using a platinum-sensitive PDX
model, we further established that combination treatment resulted in
superior antitumor activity in vivo compared with single-agent
exposure and, most importantly, that the IMGN853/carboplatin
combination was more efficacious (in terms of inducing CRs) than
corresponding carboplatin/paclitaxel and carboplatin/PLD doublets
in the same model. The higher incidence of CRs is strongly indicative
of a better durability of response for the combination, and overall, the
data suggest that combining IMGN853 with carboplatin may
represent a promising approach for optimizing response to platinum
therapy in EOC.
Patients with recurrent, platinum-resistant disease pose a particular
challenge for clinicians, with therapeutic options largely limited to
chemotherapeutics with mechanisms of action distinct from the
platinum compounds, an approach which typically carries no
Figure 4. Combination IMGN853 plus bevacizumab treatment disrupts tumor vascularization and causes rapid tumor destruction in OV-90
xenografts. (A) OV-90 tumor-bearing mice were treated with a single dose of vehicle, IMGN853 (2.5 mg/kg), bevacizumab (5 mg/kg), or
IMGN853 plus bevacizumab, and tumors were harvested 4 days later. Histological staining (H&E) revealed the presence of large, central
necrotic zones in tumors from combination-treated mice. Original magnification, 4×; scale bars, 2 mm (for combination panel, 600 μm).
(B) Tumor extracts were immunoblotted for γH2AX or actin (loading control) as indicated. (C) Immunohistochemical evaluation of CD31
expression (upper panel) and maytansine detection (anti-MAY; lower panel) in tumor tissues on day 4. For each group, representative
micrographs from one of three tumors are shown. Original magnification, 20×; scale bars, 200 μm.
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in the management of refractory and/or recurrent EOC. PLD is
approved as both standard monotherapy as well as a combination
partner for bevacizumab in platinum-resistant EOC [51] and has also
been combined with carboplatin in the upfront setting, where it
displays similar efficacy with a more favorable safety profile compared
with the platinum/paclitaxel doublet [52]. In this study, we found
that the synergistic improvements in antitumor activity seen with the
IMGN853/PLD combination in vitro translated to improved and
durable efficacy over the respective single-agent treatments and,
importantly, exhibited good tolerability in a platinum-resistant PDX
model. Combinatorial benefit has previously been reported for PLD
with the folate-cytotoxic agent conjugate vintafolide in preclinical
EOC models [53], which prompted late-stage clinical evaluations of
that combination in subsequent phase II and III human trials [47].
IMGN853 possesses a broader spectrum of bioactivity relative to
vintafolide, including clear demonstration of single-agent activity in
early clinical testing, which is likely due to a more potent payload,
longer circulation time, and “bystander cytotoxicity,” i.e., the ability
to eradicate adjacent FRα-negative or low-expressing tumor cells
[54]; thus, the findings presented here provide a compelling rationalefor the evaluation of IMGN853 alongside PLD in EOC patients with
recurrent disease.
A significant finding of the present study was the markedly
improved antitumor activity afforded by the combination of
IMGN853 and bevacizumab, which caused robust tumor regressions
and complete responses in two separate platinum-resistant EOC
xenograft models. A VEGF-neutralizing antibody, bevacizumab is the
only antiangiogenic agent indicated for use in EOC [37]. Because of
its high dependence on angiogenic factors during tumor progression,
ovarian cancer has long been considered amenable for the application
of this class of therapeutics [55]. Notably, in the pivotal studies that
led to approval of bevacizumab, efficacy was only demonstrated with
regard to progression-free survival, with less reliable effects seen on
overall survival, and this pattern has repeated in more recent clinical
evaluations of other antiangiogenic agents [56]. Thus, an opportunity
exists to further improve the efficacy of antiangiogenic therapy in this
disease, and it is reasonable to suggest that tailored treatment
strategies with optimized combinatorial partners such as IMGN853
are an avenue that warrants further investigation.
The mechanism by which IMGN853 achieved improved
therapeutic indices in combination with bevacizumab is yet to be
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and target distinct compartments; IMGN853 activity is directed
toward FRα-positive tumor cells, whereas bevacizumab exerts its
effects within the tumor microenvironment. We observed rapid
tumor growth arrest (within 4 days) seen in OV-90 tumor-bearing
mice following a single combination treatment associated with
extensive necrotic destruction of the tumor mass. One possibility
currently under investigation is that the presence of bevacizumab
promotes better tumor penetration and exposure to the ADC,
resulting in more effective eradication of tumor cells. In this
regard, it is well established that bevacizumab treatment can
induce normalization of the tumor vasculature, an effect that
has been suggested to result in reduced interstitial pressures and
improved drug delivery [57]. However, there are preclinical and
clinical observations of reduced tumor uptake of both chemotherapeu-
tic drugs and antibodies following antiangiogenic therapy (reviewed
in [58]). Furthermore, additive and synergistic effects between
bevacizumab and clinically relevant cytotoxics, including paclitaxel,
have also been reported in a number of xenograft studies [59–61], and
the underlying mechanisms of such interactions remain poorly defined.
Conclusion
Overall, the capacity of IMGN853 to augment the in vivo activity of
approved chemotherapeutic and biologic agents suggests that this
FRα-targeting ADC holds considerable promise for the future
management of EOC, particularly as part of novel combinatorial
strategies with existing standard-of-care regimens. Moreover, the
findings of this study have provided a framework for the optimal
design of IMGN853-based therapies for improving patient outcomes
in this malignancy. In this regard, the clinical exploration of
IMGN853 in combination with established therapeutics has begun,
with a phase Ib study in FRα-positive, advanced ovarian cancer
patients (FORWARD II; NCT02606305) currently under way.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.11.002.
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